Gunnar Birgegard

Uppsala, C, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

The Progress Test of the European Hematology Association: A New Tool for Continuous Learning.

The Progress Test of the European Hematology Association: A New Tool for Continuous Learning.

Journal: HemaSphere

Published: October 11, 2022

Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet.

Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet.

Journal: The Lancet. Haematology

Published: May 14, 2021

JAK2 V617F as a Marker for Long-Term Disease Progression and Mortality in Polycythemia Vera and its Role in Economic Modeling.

JAK2 V617F as a Marker for Long-Term Disease Progression and Mortality in Polycythemia Vera and its Role in Economic Modeling.

Journal: Journal of health economics and outcomes research

Published: February 27, 2020

The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe.

The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe.

Journal: HemaSphere

Published: January 17, 2020

Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group.

Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group.

Journal: European journal of haematology

Published: October 17, 2018

Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study.

Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study.

Journal: Leukemia research

Published: August 22, 2018

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Journal: Leukemia

Published: November 27, 2017

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

Journal: Leukemia research

Published: July 08, 2017

Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.

Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.

Journal: Haematologica

Published: June 20, 2017

The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.

The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.

Journal: Current hematologic malignancy reports

Published: August 08, 2016

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.

Journal: Leukemia

Published: August 03, 2016

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.

Journal: Haematologica

Published: May 19, 2016

Showing 1-12 of 44

Last Updated: 09/26/2026